← Back to All US Stocks

Cosmos Health Inc. (COSM) Fundamental Analysis & AI Grade 2026

COSM Nasdaq Wholesale-Drugs, Proprietaries & Druggists' Sundries NV CIK: 0001474167
Updated This Month • Analysis: May 23, 2026 • SEC Data: 2026-03-31
Combined AI Grade
D
90% Confidence
STRONG AGREEMENT
D
90% Conf
D
90% Conf

📊 COSM Key Takeaways

Revenue: $17.9M
Net Margin: -15.6%
Free Cash Flow: $-1.1M
Current Ratio: 1.08x
Debt/Equity: 0.17x
EPS: $-0.06
AI Grade: D with 90% confidence
Cosmos Health Inc. (COSM) receives a D fundamental grade with 90% confidence from our AI analysis based on SEC 10-K filings. With revenue of $17.9M, net profit margin of -15.6%, and return on equity (ROE) of -14.1%, Cosmos Health Inc. demonstrates mixed fundamentals in the Market sector. Below is our complete COSM stock analysis for 2026.

Is Cosmos Health Inc. (COSM) a Good Investment?

Claude

Cosmos Health is operationally unprofitable with negative cash flow, burning through minimal cash reserves at an unsustainable rate. The company's critically weak 7.7% gross margin in the low-margin wholesale drug distribution business cannot support operating expenses, leaving only 5-6 months of cash runway before potential liquidity crisis.

ChatGPT

Cosmos Health's fundamentals remain weak: revenue growth is minimal, gross margin is thin at 12.8%, and the business is still deeply unprofitable at both operating and net levels. Financial flexibility looks constrained by sub-1.0 current liquidity, very low cash, negative operating cash flow, and negative interest coverage, which together raise concern about near-term funding needs. While losses and EPS improved year over year, the improvement does not yet offset the company's poor growth quality and fragile balance-sheet liquidity.

Cosmos Health Inc. Key Strengths (COSM)

Claude
  • + Revenue growing 19.9% year-over-year demonstrates persistent market demand
  • + Reasonable debt/equity ratio of 0.17x avoids extreme leverage risk
  • + EPS improving 46.2% YoY from prior year loss indicates partial cost control progress
ChatGPT
  • + Revenue is still growing modestly year over year, indicating the business has not stalled completely
  • + Leverage is not extreme, with debt-to-equity of 0.23x and long-term debt at a manageable absolute level
  • + Book equity remains positive at $23.13M, providing some balance-sheet cushion

COSM Stock Risks: Cosmos Health Inc. Investment Risks

Claude
  • ! Catastrophic cash depletion: $514.7K cash against $1.1M quarterly operating cash burn provides critical liquidity crisis within months
  • ! Negative operating cash flow proves core business is value-destructive; company cannot self-fund operations
  • ! Gross margin of 7.7% structurally insufficient to cover operating expenses in a low-margin wholesale distribution business
ChatGPT
  • ! Persistent operating and net losses show the core business model is not yet generating sustainable profitability
  • ! Liquidity is tight, with a 0.99x current ratio, 0.84x quick ratio, and less than $1M of cash
  • ! Negative operating cash flow and free cash flow increase the risk of external financing or dilution if losses continue

Key Metrics to Watch

Claude
  • * Cash balance trajectory and monthly burn rate - determines solvency timeline
  • * Gross margin expansion - critical to achieving operational breakeven and sustainability
  • * Operating cash flow inflection - must achieve positive OCF to prove business model viability
ChatGPT
  • * Operating cash flow and cash balance
  • * Gross margin and operating margin

Cosmos Health Inc. (COSM) Financial Metrics & Key Ratios

Revenue
$17.9M
Net Income
$-2.8M
EPS (Diluted)
$-0.06
Free Cash Flow
$-1.1M
Total Assets
$62.4M
Cash Position
$514.7K

💡 AI Analyst Insight

Cosmos Health Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

COSM Profit Margin, ROE & Profitability Analysis

Gross Margin 7.7%
Operating Margin -12.2%
Net Margin -15.6%
ROE -14.1%
ROA -4.5%
FCF Margin -6.0%

COSM vs Market Sector: How Cosmos Health Inc. Compares

How Cosmos Health Inc. compares to Market sector averages

Net Margin
COSM -15.6%
vs
Sector Avg 12.0%
COSM Sector
ROE
COSM -14.1%
vs
Sector Avg 15.0%
COSM Sector
Current Ratio
COSM 1.1x
vs
Sector Avg 1.8x
COSM Sector
Debt/Equity
COSM 0.2x
vs
Sector Avg 0.7x
COSM Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Cosmos Health Inc. Stock Overvalued? COSM Valuation Analysis 2026

Based on fundamental analysis, Cosmos Health Inc. has mixed fundamental signals relative to the Market sector in 2026.

Return on Equity
-14.1%
Sector avg: 15%
Net Profit Margin
-15.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.17x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Cosmos Health Inc. Balance Sheet: COSM Debt, Cash & Liquidity

Current Ratio
1.08x
Quick Ratio
0.92x
Debt/Equity
0.17x
Debt/Assets
68.2%
Interest Coverage
-5.16x
Long-term Debt
$3.5M

COSM Revenue & Earnings Growth: 5-Year Financial Trend

COSM 5-year financial data: Year 2021: Revenue $56.2M, Net Income $820.8K, EPS $0.06. Year 2022: Revenue $56.2M, Net Income -$8.0M, EPS $-23.74. Year 2023: Revenue $53.4M, Net Income -$13.8M, EPS $-33.16. Year 2024: Revenue $54.4M, Net Income -$18.5M, EPS $-2.15. Year 2025: Revenue $65.3M, Net Income -$16.2M, EPS $-1.17.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Cosmos Health Inc.'s revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.17 indicates the company is currently unprofitable.

COSM Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-6.0%
Free cash flow / Revenue

COSM Quarterly Earnings & Performance

Quarterly financial performance data for Cosmos Health Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $13.7M -$818.1K $-0.03
Q3 2025 $12.4M -$5.4M $-0.17
Q2 2025 $13.2M -$2.6M $-0.10
Q1 2025 $13.7M -$818.1K $-0.03
Q3 2024 $12.4M -$459.9K $-0.27
Q2 2024 $12.4M -$459.9K $-0.09
Q1 2024 $12.3M -$459.9K $-0.04
Q3 2023 $12.0M $203.3K $-0.27

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Cosmos Health Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$1.1M
Cash generated from operations
Capital Expenditures
$11.4K
Investment in assets
Dividends
None
No dividend program

COSM SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Cosmos Health Inc. (CIK: 0001474167)

📋 Recent SEC Filings

Date Form Document Action
Jun 2, 2026 DEF 14A cosm_def14a.htm View →
May 22, 2026 8-K cosm_8k.htm View →
May 20, 2026 10-Q cosm_10q.htm View →
Apr 16, 2026 8-K cosm_8k.htm View →
Apr 15, 2026 10-K cosm_10k.htm View →

Frequently Asked Questions about COSM

What is the AI rating for COSM?

Cosmos Health Inc. (COSM) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are COSM's key strengths?

Claude: Revenue growing 19.9% year-over-year demonstrates persistent market demand. Reasonable debt/equity ratio of 0.17x avoids extreme leverage risk. ChatGPT: Revenue is still growing modestly year over year, indicating the business has not stalled completely. Leverage is not extreme, with debt-to-equity of 0.23x and long-term debt at a manageable absolute level.

What are the risks of investing in COSM?

Claude: Catastrophic cash depletion: $514.7K cash against $1.1M quarterly operating cash burn provides critical liquidity crisis within months. Negative operating cash flow proves core business is value-destructive; company cannot self-fund operations. ChatGPT: Persistent operating and net losses show the core business model is not yet generating sustainable profitability. Liquidity is tight, with a 0.99x current ratio, 0.84x quick ratio, and less than $1M of cash.

What is COSM's revenue and growth?

Cosmos Health Inc. reported revenue of $17.9M.

Does COSM pay dividends?

Cosmos Health Inc. does not currently pay dividends.

Where can I find COSM SEC filings?

Official SEC filings for Cosmos Health Inc. (CIK: 0001474167) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is COSM's EPS?

Cosmos Health Inc. has a diluted EPS of $-0.06.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is COSM's fundamental grade?

Based on our AI fundamental analysis in June 2026, Cosmos Health Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is COSM stock overvalued or undervalued?

Valuation metrics for COSM: ROE of -14.1% (sector avg: 15%), net margin of -15.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is COSM's AI grade for 2026?

Our dual AI analysis gives Cosmos Health Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is COSM's free cash flow?

Cosmos Health Inc.'s operating cash flow is $-1.1M, with capital expenditures of $11.4K. FCF margin is -6.0%.

How does COSM compare to other Market stocks?

Vs Default sector averages: Net margin -15.6% (avg: 12%), ROE -14.1% (avg: 15%), current ratio 1.08 (avg: 1.8).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% AVGO 87% DECK 87%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 23, 2026 | Data as of: 2026-03-31 | Powered by Claude AI